Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
QURE

QURE - uniQure NV Stock Price, Fair Value and News

$23.02-1.35 (-5.54%)
Market Closed

7/100

QURE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

7/100

QURE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$20.06

Target 3M

$22.57

Target 6M

$21.32

QURE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

QURE Price Action

Last 7 days

5.9%

Last 30 days

-6.3%

Last 90 days

-66.1%

Trailing 12 Months

50.3%

QURE RSI Chart

QURE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

QURE Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-6.1

Price/Sales (Trailing)

91.04

EV/EBITDA

-4.69

Price/Free Cashflow

-9.34

QURE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$20.06

Target 3M

$22.57

Target 6M

$21.32

QURE Fundamentals

QURE Revenue

Revenue (TTM)

15.8M

Rev. Growth (Yr)

61.83%

Rev. Growth (Qtr)

-29.67%

QURE Earnings

Earnings (TTM)

-235.1M

Earnings Growth (Yr)

-81.46%

Earnings Growth (Qtr)

-113.5%

QURE Profitability

EBT Margin

-1426.85%

Return on Equity

-102.8%

Return on Assets

-26.47%

Free Cashflow Yield

-10.71%

QURE Investor Care

Shares Dilution (1Y)

27.80%

Diluted EPS (TTM)

-4.38

QURE Alerts

  • 2 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202520.2M14.3M15.8M0
202419.0M27.7M28.6M27.1M
2023108.3M110.1M111.9M15.8M
2022419.6M315.2M210.9M106.5M
2021159.1M280.8M402.4M524.0M
202014.8M22.4M30.0M37.5M
20198.9M8.4M6.3M7.3M
201813.3M11.4M12.3M11.3M
201724.1M24.6M19.7M13.1M
201614.2M17.8M21.5M25.1M
201500010.6M
20140006.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About uniQure NV

QURE
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
 CEO
 WEBSITEuniqure.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES501

uniQure NV Frequently Asked Questions

QURE is the stock ticker symbol of uniQure NV. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of uniQure NV is 1.43 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check QURE's fair value in chart for subscribers.

The fair value guage provides a quick view whether QURE is over valued or under valued. Whether uniQure NV is cheap or expensive depends on the assumptions which impact uniQure NV's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for QURE.

As of Wed Jan 28 2026, QURE's PE ratio (Price to Earnings) is -6.1 and Price to Sales (PS) ratio is 91.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. QURE PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, uniQure NV has provided 0.024 (multiply by 100 for percentage) rate of return.